^
Association details:
| Biomarker: | SETD2 mutation + MGMT promoter methylation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Temodex (temozolomide gel) (DNA synthesis inhibitor, Alkylating agent) |
| Direction: | Resistant |
Evidence:
Source:
Title:
SetD2 histone methyltransferase mutation status predicts treatment response in glioblastoma: Strategies to overcome chemoresistance
Excerpt:
Our TCGA database analysis reveals that SETD2 mutations are associated with reduced overall survival in patients with methylated MGMT promotor who received temozolomide suggesting that mutation of SETD2 is a predictive marker for chemotherapy resistance in GBM.
